Theresa Madigan1, James R Johnson2, Connie Clabots2, Brian D Johnston2, Stephen B Porter2, Billie S Slater2, Ritu Banerjee3. 1. Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester. 2. Veterans Affairs Medical Center University of Minnesota, Minneapolis. 3. Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester Division of Pediatric Infectious Diseases, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND: Reasons for the successful global dissemination of multidrug-resistant Escherichia coli sequence type 131 (ST131) are undefined, but may include enhanced transmissibility or ability to colonize the intestine compared with other strains. METHODS: We identified a household in which 2 young children had urinary tract infection (UTI) caused by an extended-spectrum β-lactamase (ESBL)-producing, multidrug-resistant ST131 E. coli strain. We assessed the prevalence of ST131 intestinal colonization among the 7 household members (6 humans, 1 dog). Fecal samples, collected 3 times over a 19-week period, were cultured selectively for E. coli. Isolates were characterized using clone-specific polymerase chain reaction to detect ST131 and its ESBL-associated H30Rx subclone, pulsed-field gel electrophoresis, extended virulence genotyping, and antimicrobial susceptibility testing. RESULTS: In total, 8 different E. coli pulsotypes (strains) were identified. The index patient's urine isolate represented ST131-H30Rx strain 903. This was the most widely shared and persistent strain in the household, colonizing 5 individuals at each sampling. In contrast, the 7 non-ST131 strains were each found in only 1 or 2 household members at a time, with variable persistence. The ST131 strain was the only strain with both extensive virulence and antimicrobial resistance profiles. CONCLUSIONS: An ESBL-producing ST131-H30Rx strain caused UTI in 2 siblings, plus asymptomatic intestinal colonization in multiple other household members, and was the household's most extensively detected and persistent fecal E. coli strain. Efficient transmission and intestinal colonization may contribute to the epidemiologic success of the H30Rx subclone of E. coli ST131.
BACKGROUND: Reasons for the successful global dissemination of multidrug-resistant Escherichia coli sequence type 131 (ST131) are undefined, but may include enhanced transmissibility or ability to colonize the intestine compared with other strains. METHODS: We identified a household in which 2 young children had urinary tract infection (UTI) caused by an extended-spectrum β-lactamase (ESBL)-producing, multidrug-resistant ST131E. coli strain. We assessed the prevalence of ST131 intestinal colonization among the 7 household members (6 humans, 1 dog). Fecal samples, collected 3 times over a 19-week period, were cultured selectively for E. coli. Isolates were characterized using clone-specific polymerase chain reaction to detect ST131 and its ESBL-associated H30Rx subclone, pulsed-field gel electrophoresis, extended virulence genotyping, and antimicrobial susceptibility testing. RESULTS: In total, 8 different E. coli pulsotypes (strains) were identified. The index patient's urine isolate represented ST131-H30Rx strain 903. This was the most widely shared and persistent strain in the household, colonizing 5 individuals at each sampling. In contrast, the 7 non-ST131 strains were each found in only 1 or 2 household members at a time, with variable persistence. The ST131 strain was the only strain with both extensive virulence and antimicrobial resistance profiles. CONCLUSIONS: An ESBL-producing ST131-H30Rx strain caused UTI in 2 siblings, plus asymptomatic intestinal colonization in multiple other household members, and was the household's most extensively detected and persistent fecal E. coli strain. Efficient transmission and intestinal colonization may contribute to the epidemiologic success of the H30Rx subclone of E. coli ST131.
Authors: Krystina L Woods; James R Johnson; Sofia Padkowsky; Noriel Mariano; Rita Colon-Urban; Mahmoud Hassanein; Wehbeh Wehbeh; Brian D Johnston; Connie Clabots; Saadia Zahid; Carl Urban Journal: Antimicrob Agents Chemother Date: 2012-01-17 Impact factor: 5.191
Authors: James R Johnson; Stephen B Porter; George Zhanel; Michael A Kuskowski; Erick Denamur Journal: Infect Immun Date: 2012-02-06 Impact factor: 3.441
Authors: Betsy Foxman; Shannon D Manning; Patricia Tallman; Richard Bauer; Lixin Zhang; James S Koopman; Brenda Gillespie; Jack D Sobel; Carl F Marrs Journal: Am J Epidemiol Date: 2002-12-15 Impact factor: 4.897
Authors: James R Johnson; Brian Johnston; Connie Clabots; Michael A Kuskowski; Mariana Castanheira Journal: Clin Infect Dis Date: 2010-08-01 Impact factor: 9.079
Authors: James R Johnson; Andrew C Murray; Abby Gajewski; Maureen Sullivan; Paula Snippes; Michael A Kuskowski; Kirk E Smith Journal: Antimicrob Agents Chemother Date: 2003-07 Impact factor: 5.191
Authors: Katherine E Goodman; Justin Lessler; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Jennifer H Han; Aaron M Milstone; Colin J Massey; Pranita D Tamma Journal: Clin Infect Dis Date: 2016-06-28 Impact factor: 9.079
Authors: Nina M Poole; Sabrina I Green; Anubama Rajan; Luz E Vela; Xi-Lei Zeng; Mary K Estes; Anthony W Maresso Journal: Infect Immun Date: 2017-10-18 Impact factor: 3.441
Authors: David X Li; Anna C Sick-Samuels; Nuntra Suwantarat; Rebecca G Same; Patricia J Simner; Pranita D Tamma Journal: Infect Control Hosp Epidemiol Date: 2017-12-05 Impact factor: 3.254
Authors: Muhanad Mohamed; Connie Clabots; Stephen B Porter; Tricia Bender; Paul Thuras; James R Johnson Journal: J Infect Dis Date: 2020-04-27 Impact factor: 5.226
Authors: Nuntra Suwantarat; Latania K Logan; Karen C Carroll; Robert A Bonomo; Patricia J Simner; Susan D Rudin; Aaron M Milstone; Tsigereda Tekle; Tracy Ross; Pranita D Tamma Journal: Infect Control Hosp Epidemiol Date: 2016-02-09 Impact factor: 3.254
Authors: Shehara M Mendis; Shawn Vasoo; Brian D Johnston; Stephen B Porter; Scott A Cunningham; Sanjay R Menon; Christine B Teng; Partha P De; Robin Patel; James R Johnson; Ritu Banerjee Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191
Authors: James R Johnson; Brian D Johnston; Parissa Delavari; Paul Thuras; Connie Clabots; Michael J Sadowsky Journal: Appl Environ Microbiol Date: 2017-12-01 Impact factor: 4.792